Hospital
Virginia Hospital Center Arlington Health System
Virginia Hospital Center Arlington Health System was paid $31.00M by Medicaid between Jan 2018 and Dec 2024, across 313 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoVIRGINIA HOSPITAL CENTER ARLINGTON HEALTH SYSTEM
ARLINGTON, VA 22205
ARLINGTON, VA 22205
33aNPI1790785996assigned 07/28/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$31.00M
24GClaims948,424
24DCodes billed313
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#25 of 80
Median peer was paid$14.69M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 90,219 | $1.92M | |
| 2019 | 114,441 | $2.90M | |
| 2020 | 84,450 | $2.57M | |
| 2021 | 123,056 | $3.66M | |
| 2022 | 167,113 | $5.54M | |
| 2023 | 199,225 | $7.46M | |
| 2024incomplete | 169,920 | $6.94M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 36,179 | 30,004 | $6.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 26,483 | 22,059 | $4.57M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.9% | 14,355 | 12,109 | $2.44M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.3% | 6,877 | 6,001 | $1.64M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.0% | 7,163 | 6,000 | $1.24M |
| G0378 | Hospital observation service, per hour | 3.2% | 8,939 | 5,660 | $990K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.1% | 8,455 | 5,357 | $946K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.9% | 23,202 | 6,520 | $888K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 6,167 | 5,130 | $811K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 5,320 | 3,051 | $664K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.1% | 7,454 | 5,043 | $638K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.6% | 15,941 | 4,892 | $505K |
301 more codes
| 59025 | Fetal non-stress test | 1.6% | 2,470 | $491K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.6% | 1,648 | $482K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.6% | 1,841 | $481K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 1,947 | $370K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 1,529 | $356K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.0% | 2,907 | $320K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,550 | $300K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 17,191 | $297K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,514 | $235K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 682 | $234K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,326 | $214K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,165 | $211K |
| 97162 | <1% | 2,724 | $209K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 11,563 | $195K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,058 | $177K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,092 | $173K |
| 76818 | <1% | 1,745 | $171K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,768 | $162K |
| 80053 | Comprehensive metabolic panel | <1% | 46,782 | $161K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 239 | $147K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 182 | $143K |
| 70496 | <1% | 602 | $141K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,594 | $135K |
| 97163 | <1% | 1,286 | $129K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 11,817 | $124K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 694 | $115K |
| 93971 | <1% | 1,557 | $111K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,463 | $111K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 967 | $103K |
| 93976 | <1% | 1,782 | $102K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,169 | $101K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,811 | $98K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,651 | $94K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 145 | $92K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 670 | $92K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 789 | $91K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,512 | $87K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,391 | $80K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,445 | $77K |
| 76801 | <1% | 1,425 | $73K | |
| 76770 | <1% | 651 | $70K | |
| 97161 | <1% | 636 | $67K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,756 | $63K |
| 85027 | <1% | 56,217 | $63K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,454 | $61K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,676 | $61K |
| 97166 | <1% | 1,160 | $60K | |
| 97116 | <1% | 2,567 | $53K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 270 | $52K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 178 | $51K |
| 36415 | Collection of venous blood by venipuncture | <1% | 38,633 | $49K |
| 90715 | <1% | 1,489 | $47K | |
| 71250 | <1% | 896 | $46K | |
| 93970 | <1% | 433 | $44K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 73 | $42K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,485 | $42K |
| 77080 | <1% | 880 | $40K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,793 | $39K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,506 | $38K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,270 | $36K |
| 81003 | <1% | 10,658 | $35K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,012 | $33K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,107 | $33K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 212 | $32K |
| 87040 | <1% | 3,724 | $31K | |
| 86850 | <1% | 6,213 | $30K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,916 | $29K |
| 83880 | <1% | 3,633 | $28K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 353 | $27K |
| 36430 | <1% | 142 | $26K | |
| 12001 | <1% | 127 | $23K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 43 | $21K |
| 93017 | <1% | 390 | $20K | |
| 73562 | <1% | 2,899 | $20K | |
| 84484 | <1% | 17,171 | $19K | |
| 76642 | <1% | 214 | $19K | |
| 70486 | <1% | 554 | $19K | |
| 76536 | <1% | 204 | $19K | |
| 72131 | <1% | 446 | $18K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,515 | $18K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 796 | $18K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,858 | $17K |
| 29125 | <1% | 310 | $17K | |
| 0002A | <1% | 477 | $17K | |
| 0001A | <1% | 486 | $15K | |
| 73630 | <1% | 2,351 | $15K | |
| 73610 | <1% | 1,986 | $14K | |
| 73030 | <1% | 1,879 | $13K | |
| 85610 | <1% | 8,599 | $13K | |
| 83605 | <1% | 6,670 | $13K | |
| 85379 | <1% | 3,136 | $12K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 151 | $12K |
| 73130 | <1% | 1,886 | $11K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 57 | $11K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,373 | $11K |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 769 | $10K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,163 | $10K |
| 86592 | <1% | 1,329 | $10K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,371 | $10K |
| 99153 | Mod sedat endo service >5yrs | <1% | 300 | $10K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 130 | $9K |
| 81001 | <1% | 15,961 | $9K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,175 | $8K |
| 87486 | <1% | 1,743 | $8K | |
| 90686 | <1% | 433 | $8K | |
| 76813 | <1% | 150 | $8K | |
| 94762 | <1% | 2,019 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,021 | $7K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 83 | $7K |
| 77336 | <1% | 116 | $7K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 12 | $7K |
| 82962 | <1% | 16,504 | $7K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 122 | $6K |
| 29515 | <1% | 70 | $6K | |
| 86762 | <1% | 404 | $6K | |
| 12011 | <1% | 43 | $6K | |
| 86803 | <1% | 431 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,815 | $6K |
| 94664 | <1% | 472 | $6K | |
| 72197 | <1% | 16 | $6K | |
| 86900 | <1% | 6,512 | $5K | |
| 84702 | <1% | 1,725 | $5K | |
| 88342 | <1% | 1,213 | $5K | |
| 84145 | <1% | 1,004 | $5K | |
| 86901 | <1% | 6,513 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 18,688 | $5K |
| 87581 | <1% | 1,758 | $5K | |
| 97165 | <1% | 178 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,548 | $5K |
| 70498 | <1% | 575 | $5K | |
| 29240 | <1% | 29 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,012 | $5K |
| 87070 | <1% | 2,456 | $5K | |
| 97597 | <1% | 317 | $5K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 136 | $4K |
| 73110 | <1% | 1,010 | $4K | |
| 74018 | <1% | 290 | $4K | |
| 80061 | Lipid panel | <1% | 2,372 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,277 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,304 | $4K |
| 73502 | <1% | 496 | $4K | |
| 76870 | <1% | 39 | $4K | |
| 87653 | <1% | 38 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,274 | $4K |
| 82950 | <1% | 743 | $4K | |
| 77066 | Tomosynthesis, mammo | <1% | 192 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,369 | $4K |
| 82565 | <1% | 2,335 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,265 | $3K |
| 85730 | <1% | 6,825 | $3K | |
| 72100 | <1% | 298 | $3K | |
| 84703 | <1% | 4,559 | $3K | |
| 84439 | <1% | 1,478 | $3K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 15 | $3K |
| 94799 | <1% | 695 | $3K | |
| 81025 | <1% | 4,739 | $3K | |
| 73080 | <1% | 342 | $3K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,475 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,364 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 597 | $3K |
| 82247 | <1% | 308 | $2K | |
| 72110 | <1% | 87 | $2K | |
| 83690 | <1% | 11,350 | $2K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 880 | $2K |
| 96376 | <1% | 5,872 | $2K | |
| 84156 | <1% | 519 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 62 | $2K |
| 83735 | <1% | 6,580 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,402 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 6,059 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,876 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 582 | $2K |
| 0352U | <1% | 202 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,900 | $1K |
| 86923 | <1% | 76 | $1K | |
| J3490 | Unclassified drugs | <1% | 2,850 | $1K |
| 76820 | <1% | 24 | $1K | |
| 87186 | <1% | 3,088 | $1K | |
| 70491 | <1% | 12 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 825 | $1K |
| 97167 | <1% | 34 | $1K | |
| 82803 | <1% | 939 | $1K | |
| 87420 | <1% | 122 | $1K | |
| 82248 | <1% | 1,072 | $1K | |
| 82951 | <1% | 70 | $1K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,188 | $1K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 18 | $1K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,887 | $1K |
| 96367 | <1% | 102 | $1K | |
| 80306 | <1% | 753 | $1K | |
| 10060 | <1% | 13 | $1K | |
| 99152 | <1% | 924 | $928.67 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,845 | $861.09 |
| 82728 | <1% | 468 | $857.78 | |
| 82607 | <1% | 415 | $843.17 | |
| 73590 | <1% | 240 | $840.82 | |
| 72128 | <1% | 63 | $803.06 | |
| 86140 | <1% | 1,026 | $772.77 | |
| 87015 | <1% | 245 | $737.12 | |
| 87340 | <1% | 346 | $734.95 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,370 | $679.11 |
| 77062 | <1% | 12 | $590.61 | |
| 88313 | <1% | 634 | $585.60 | |
| 82550 | <1% | 1,378 | $559.82 | |
| 72132 | <1% | 12 | $545.78 | |
| 83550 | <1% | 522 | $524.07 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 578 | $510.77 |
| 73090 | <1% | 109 | $498.29 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,137 | $485.58 |
| 87205 | <1% | 1,504 | $476.33 | |
| 87430 | <1% | 662 | $474.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,010 | $473.68 |
| 88304 | <1% | 211 | $465.71 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,118 | $460.55 |
| 83540 | <1% | 556 | $414.20 | |
| 84100 | <1% | 2,226 | $410.46 | |
| 87081 | <1% | 705 | $396.27 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,712 | $371.69 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 841 | $371.26 |
| G0008 | Administration of influenza virus vaccine | <1% | 162 | $363.45 |
| 82570 | <1% | 490 | $350.82 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 8,665 | $344.99 |
| 85652 | <1% | 1,189 | $336.68 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,409 | $282.87 |
| 72170 | <1% | 82 | $281.41 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,030 | $270.27 |
| 88142 | <1% | 13 | $265.50 | |
| 82952 | <1% | 71 | $256.93 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,188 | $233.93 |
| 88112 | <1% | 13 | $227.90 | |
| 87075 | <1% | 183 | $209.69 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 364 | $184.36 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,147 | $181.36 |
| 85018 | <1% | 307 | $170.58 | |
| 94760 | <1% | 798 | $162.21 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,034 | $159.44 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 296 | $146.75 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,564 | $136.02 |
| 83970 | <1% | 38 | $123.15 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 53 | $120.68 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 202 | $114.75 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 224 | $94.00 |
| 94644 | <1% | 14 | $74.27 | |
| 84550 | <1% | 162 | $73.29 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 702 | $57.00 |
| 82010 | <1% | 380 | $45.61 | |
| 86706 | <1% | 12 | $45.20 | |
| 84153 | <1% | 13 | $44.94 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 339 | $39.58 |
| 83615 | <1% | 70 | $32.21 | |
| 82043 | <1% | 30 | $28.95 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 30 | $26.78 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 18 | $26.13 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 75 | $23.66 |
| 82040 | <1% | 30 | $20.96 | |
| 87899 | <1% | 34 | $18.88 | |
| 87808 | <1% | 258 | $17.85 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 112 | $13.66 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 159 | $12.38 |
| 85014 | <1% | 155 | $11.67 | |
| 99001 | <1% | 309 | $11.29 | |
| 85347 | <1% | 20 | $10.34 | |
| 87210 | <1% | 235 | $9.19 | |
| 82746 | <1% | 26 | $8.75 | |
| 84460 | <1% | 29 | $8.09 | |
| 84450 | <1% | 28 | $8.09 | |
| 84075 | <1% | 29 | $8.09 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 20 | $4.64 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 51 | $4.62 |
| C1769 | Guide wire | <1% | 1,132 | $3.37 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 17 | $1.92 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 483 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 434 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 543 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 12 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 15 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 390 | $0.00 |
| 86703 | 0% | 17 | $0.00 | |
| 88312 | 0% | 91 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 45 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 113 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 13 | $0.00 |
| 29505 | 0% | 24 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 31 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 128 | $0.00 |
| A6022 | Collagen dressing, sterile, size more than 16 sq. in. but less than or equal to 48 sq. in., each | 0% | 35 | $0.00 |
| 86308 | 0% | 51 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 150 | $0.00 |
| 36416 | 0% | 121 | $0.00 | |
| 88341 | 0% | 20 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 228 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 249 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 33 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 76 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 149 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 635 | $0.00 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | 0% | 111 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 19 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 33 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 22 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZABROWSKI, JOHN (SENIOR VICE PRESIDENT / CFO)
| Provider | Location | Paid |
|---|---|---|
| Arlington Urgent Care, LLC | Arlington, VA | $200.68 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.